The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260083678A1, concerning oral dosing methods for GLP-1 compounds. The application, filed on December 3, 2025, by inventors Flemming S. Nielsen and Per Sauerberg, details improved uses of GLP-1 peptides in oral therapy, with CPC classifications including A61K 9/2013 and A61K 38/26.

This publication represents a new patent application and does not impose immediate regulatory obligations on drug manufacturers. However, it signifies potential future intellectual property developments in the field of GLP-1 therapies. Companies involved in the development or marketing of GLP-1 based drugs should monitor this patent application and related filings for potential impacts on their product pipelines and market exclusivity.